These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18212301)

  • 21. [Prevention of diabetic angiopathy or revision of the concept of control and compensation of diabetes and of its practical management].
    Scapellato L
    Boll Soc Ital Cardiol; 1974; 19(7):731-8. PubMed ID: 4464970
    [No Abstract]   [Full Text] [Related]  

  • 22. Incretins and pancreatitis--what happens next? A personal viewpoint.
    Robson J
    Diabet Med; 2013 Oct; 30(10):1156-9. PubMed ID: 24073726
    [No Abstract]   [Full Text] [Related]  

  • 23. Diabetes drug may also benefit blood vessels.
    Mayo Clin Health Lett; 2003 Nov; 21(11):4. PubMed ID: 14679928
    [No Abstract]   [Full Text] [Related]  

  • 24. What's in a name?
    Gottlieb SH
    Diabetes Forecast; 2002 Dec; 55(12):30-1, 33. PubMed ID: 14768616
    [No Abstract]   [Full Text] [Related]  

  • 25. [ACCORD (Action to Control Cardiovascular Risk in Diabetes trial) becoming "two-tone"].
    Seufert J
    Dtsch Med Wochenschr; 2008 May; 133(20):1068-70. PubMed ID: 18461525
    [No Abstract]   [Full Text] [Related]  

  • 26. Anti-inflammatory Strategies to Prevent Diabetic Cardiovascular Disease.
    Jialal I; Devaraj S
    Clin Pharmacol Ther; 2015 Aug; 98(2):121-3. PubMed ID: 25732108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid-lowering treatment for all could substantially reduce the burden of macrovascular complications of diabetes patients in the Netherlands.
    Jacobs-van der Bruggen MA; Engelfriet PM; Hoogenveen RT; van Baal PH; Struijs JN; Verschuren WM; Smit HA; Baan CA
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):521-5. PubMed ID: 18830084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Should we be more aggressive in the therapy against cardiovascular risk factors? Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill?
    Stirban AO; Tschoepe D
    Diabetes Care; 2008 Feb; 31 Suppl 2():S226-8. PubMed ID: 18227490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Point: If it is important to prevent type 2 diabetes, it is important to consider all proven therapies within a comprehensive approach.
    Gerstein HC
    Diabetes Care; 2007 Feb; 30(2):432-4. PubMed ID: 17259525
    [No Abstract]   [Full Text] [Related]  

  • 30. [Effect of acetylsalicylic acid on thrombocyte function in patients with diabetes mellitus (review of the literature)].
    Gendeleka GF; Gruzina EA
    Vrach Delo; 1987 Jan; (1):100-5. PubMed ID: 3564399
    [No Abstract]   [Full Text] [Related]  

  • 31. Thiazolidinediones and cardiovascular outcomes in type 2 diabetes.
    Grant PJ
    Heart; 2009 Feb; 95(4):332; author reply 332. PubMed ID: 19176568
    [No Abstract]   [Full Text] [Related]  

  • 32. Aspirin and Diabetes Mellitus: revisiting an old player.
    Manrique C; Lastra G; Palmer J; Gardner M; Sowers JR
    Ther Adv Cardiovasc Dis; 2008 Feb; 2(1):37-42. PubMed ID: 19124406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Heparin in the overall treatment of diabetes mellitus].
    Kozlov VV
    Vrach Delo; 1976 Jan; (1):110-2. PubMed ID: 1246836
    [No Abstract]   [Full Text] [Related]  

  • 34. Not all diabetics are created equal (in cardiovascular risk).
    Budoff MJ
    Eur Heart J; 2008 Sep; 29(18):2193-4. PubMed ID: 18687661
    [No Abstract]   [Full Text] [Related]  

  • 35. Cardiovascular disease and intensive glucose lowering in type 2 diabetes.
    Younis N; Soran H; Hassanein M
    QJM; 2009 Apr; 102(4):293-6. PubMed ID: 19147659
    [No Abstract]   [Full Text] [Related]  

  • 36. Current treatment of non-alcoholic fatty liver disease.
    Ahmed MH; Byrne CD
    Diabetes Obes Metab; 2009 Mar; 11(3):188-95. PubMed ID: 18564173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond.
    Inzucchi SE; McGuire DK
    Circulation; 2008 Jan; 117(4):574-84. PubMed ID: 18227398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
    J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular disease.
    Bloomgarden ZT
    Diabetes Care; 2006 May; 29(5):1160-6. PubMed ID: 16644657
    [No Abstract]   [Full Text] [Related]  

  • 40. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.